Semaglutide Research for Weight Loss
An evidence-based overview of research examining Semaglutide in the context of weight loss. This page synthesizes findings from peer-reviewed literature.
Research Summary
Semaglutide is FDA-approved for chronic weight management (as Wegovy) and has demonstrated substantial efficacy in multiple Phase 3 trials. The STEP 1 trial showed 14.9% mean weight loss versus 2.4% with placebo at 68 weeks (N=1,961). The mechanism involves GLP-1 receptor activation in appetite-regulating brain regions, reducing hunger and increasing satiety. Higher dose studies (STEP UP, 7.2mg) achieved 20.7% weight loss. Approximately 50% of participants achieve 15% or greater weight loss. Semaglutide represents a significant advance in pharmacological obesity treatment. In the exploratory STEP 1 extension (327 participants), the semaglutide group regained about two-thirds of its prior mean weight loss in the year after semaglutide and lifestyle intervention were discontinued (PMID:35441470).
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.